Assessment of Pancreatic Beta Cell Mass and Function by Positron Emission Tomography Imaging in Human Diabetes Mellitus
Assessment of Pancreatic Beta Cell Mass and Function with the Aid of Positron Emission Tomography Imaging in Human Diabetes Mellitus
Azienda Ospedaliero-Universitaria di Parma
70 participants
Mar 15, 2022
INTERVENTIONAL
Conditions
Summary
The goals of this project are to build an experimental tool to dissect out in vivo pancreatic beta cell mass (BCM) and beta cell function (BCF) and to assess for the first time these two determinants of beta cell functional mass (BCFxM) in obesity and in various stages of type 1 and type 2 diabetes mellitus.
Eligibility
Inclusion Criteria3
- Age ≥18 years; ≤ 75 years
- Both sexes
- Good health
Exclusion Criteria19
- Able to understand methods, goals, and implications of the research and of delivering a free, written informed consent
- Hemoglobin < 12 g/dl
- HbA1c > 10%
- Pregnancy or breast-feeding
- If not in menopause, women not using effective birth control methods or not willing to undergo a pregnancy test
- History of severe psychiatric disorder or alcohol abuse
- Recent head traumas (<6 months)
- Active neurologic diseases
- Claustrophobia
- Active malignant neoplasms
- Severe kidney and/or liver disease
- Recent (<6 months) major adverse cardiovascular events
- Heart failure (class NYHA 3-4)
- Drugs known to affect beta cell function and/or insulin sensitivity
- Current or past treatment with GLP1R-agonists
- Intolerance to exenatide
- Endocrine diseases, other than diabetes mellitus, known to affect beta cell function and/or insulin sensitivity, except well controlled hypothyroidism or adrenal insufficiency
- COPD on day time oxygen therapy
- Any current acute disease
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
68Ga-exendin4 PET-CT scan
before and after a standardized mixed meal venous blood samples will be collected at time intervals to measure plasma glucose, C-peptide,insulin, glucagon, glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) curves
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05662189